168 related articles for article (PubMed ID: 26991857)
1. Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
Delgado J; Bielig T; Bonet L; Carnero-Montoro E; Puente XS; Colomer D; Bosch E; Campo E; Lozano F
Br J Haematol; 2017 Apr; 177(1):147-150. PubMed ID: 26991857
[TBL] [Abstract][Full Text] [Related]
2. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
Nückel H; Frey UH; Bau M; Sellmann L; Stanelle J; Dürig J; Jöckel KH; Dührsen U; Siffert W
Blood; 2007 Jan; 109(1):290-7. PubMed ID: 16960146
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression.
Prieto D; Oppezzo P
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206143
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukaemia.
Hallek M; Shanafelt TD; Eichhorst B
Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
[TBL] [Abstract][Full Text] [Related]
5. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
6. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.
Nückel H; Frey UH; Dürig J; Dührsen U; Siffert W
Eur J Haematol; 2004 Apr; 72(4):259-63. PubMed ID: 15089763
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
[No Abstract] [Full Text] [Related]
8. Chronic lymphocytic leukaemia--moving towards cure?
Hillmen P
Lancet; 2010 Oct; 376(9747):1122-4. PubMed ID: 20888976
[No Abstract] [Full Text] [Related]
9. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
10. Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
Tracy I; Tapper W; Parker A; Gardiner A; Sadullah S; Pratt G; Copplestone A; Oscier D; Best OG
Br J Haematol; 2017 Sep; 178(5):824-826. PubMed ID: 27292869
[No Abstract] [Full Text] [Related]
11. Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
Friedman DR; Guadalupe E; Volkheimer A; Moore JO; Weinberg JB
Br J Haematol; 2018 Dec; 183(5):747-754. PubMed ID: 30407619
[TBL] [Abstract][Full Text] [Related]
12. An update on the management of chronic lymphocytic leukaemia.
Yee KW; O'Brien SM; Giles FJ
Expert Opin Pharmacother; 2004 Jul; 5(7):1535-54. PubMed ID: 15212604
[TBL] [Abstract][Full Text] [Related]
13. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
Burger JA
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
[No Abstract] [Full Text] [Related]
14. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Kreuzer KA; Furman RR; Stilgenbauer S; Dubowy RL; Kim Y; Munugalavadla V; Lilienweiss E; Reinhardt HC; Cramer P; Eichhorst B; Hillmen P; O'Brien SM; Pettitt AR; Hallek M
Leukemia; 2020 Jan; 34(1):296-300. PubMed ID: 31427720
[No Abstract] [Full Text] [Related]
15. High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
Tate C; Burgess M; McMillan NA; Saunders NA; Cheung C; Gill D; Mollee P
Leuk Lymphoma; 2019 Oct; 60(10):2563-2567. PubMed ID: 31237178
[No Abstract] [Full Text] [Related]
16. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
17. The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy.
Mazumdar R; Evans P; Culpin R; Bailey J; Allsup D
Leuk Res; 2013 Jun; 37(6):614-8. PubMed ID: 23522450
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
[TBL] [Abstract][Full Text] [Related]
19. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Gagez AL; Duroux-Richard I; Leprêtre S; Orsini-Piocelle F; Letestu R; De Guibert S; Tuaillon E; Leblond V; Khalifa O; Gouilleux-Gruart V; Banos A; Tournilhac O; Dupuis J; Jorgensen C; Cartron G; Apparailly F
Haematologica; 2017 Apr; 102(4):746-754. PubMed ID: 28126961
[TBL] [Abstract][Full Text] [Related]
20. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
